Summary
This study is testing a new drug called BG-75202 in people with myeloid blood cancers. Researchers want to find out:
- how safe the drug is
- what side effects it may cause
- how the body processes the drug
- how the drug affects cancer cells
- whether the drug shows signs of helping to treat myeloid cancers
BG-75202 may be given on its own or together with other anti-cancer treatments.
The study is an early-phase (Phase 1) trial, which means the main goal is to find a safe dose and learn more about how the treatment works. Researchers will also look for early signs that the treatment may help control the cancer.
Who can take part?
You may be eligible for this study if:
- you are aged 18 years or older
- you have been diagnosed with a myeloid blood cancer (myeloid malignancy)
- your cancer has come back after treatment (relapsed) or has not responded to treatment (refractory)
- you have received at least one previous treatment for your cancer
- if your cancer has a genetic change that can be treated with a targeted therapy, you must have already received that treatment, unless it was not suitable, available, or you chose not to have it.
What treatment is being studied?
This study is testing a new investigational medicine called BG-75202, which is taken by mouth. The study is being conducted in stages to find a safe and suitable dose and to learn more about how the treatment works.
In the first part of the study (Phase 1a), different dose levels of BG-75202 will be tested to help identify a suitable dose. In the second part (Phase 1b), participants will receive BG-75202 at selected dose levels to further assess its safety and effects on the cancer.
Study treatment schedule
- Phase 1a (Part A): BG-75202 taken by mouth on its own at increasing dose levels.
- Phase 1a (Part B): BG-75202 taken by mouth together with a hypomethylating agent (HMA), while researchers test increasing dose levels of BG-75202.
- Phase 1b: BG-75202 taken by mouth on its own at selected dose levels.